{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:01:02Z","timestamp":1761058862332,"version":"build-2065373602"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2008,11,6]],"date-time":"2008-11-06T00:00:00Z","timestamp":1225929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>A multicenter phase 2 trial was conducted to evaluate the safety and feasibility of radiotherapy after paclitaxel, estramustine phosphate, and carboplatin (TEC) plus androgen deprivation therapy in previously untreated unfavorable\u2010risk localized prostate cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Patients with localized high\u2010risk prostate cancer were treated with 4 cycles (16 weeks) of continuous weekly paclitaxel at 80 mg\/m<jats:sup>2<\/jats:sup> intravenously with estramustine at 280 mg orally 3 times a day for 5 days a week and carboplatin (area under the curve of 6) on Day 1 of every cycle followed by 3\u2010dimensional conformal or intensity\u2010modulated radiotherapy (total dose of 77.4 gray [Gy] in 1.8\u2010Gy fractions). All patients received androgen deprivation therapy with either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy. Patients were evaluated for acute and late toxicities along with progression\u2010free survival and time to prostate\u2010specific antigen (PSA) failure associated with the multimodality therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Twenty\u2010seven of 34 patients completed therapy and were evaluable for safety and feasibility. There was 1 patient with grade 3 nausea during chemotherapy. No other grade 3 or 4 gastrointestinal, cardiovascular, or genitourinary acute or late toxicities were reported. The most common grade 1 to 2 late toxicities were proctitis (11%), dysuria (11%), and urinary frequency\/urgency (33%). Two deaths due to prostate cancer were observed. Median follow\u2010up was 38 months among 24 surviving patients; median PSA progression\u2010free survival was 12.1 months (95% confidence interval, 13.3\u201025.9).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>Neoadjuvant chemohormonal therapy with TEC followed by high\u2010dose radiation therapy is safe and feasible in a multicenter setting. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23910","type":"journal-article","created":{"date-parts":[[2008,11,6]],"date-time":"2008-11-06T09:02:11Z","timestamp":1225962131000},"page":"3137-3145","source":"Crossref","is-referenced-by-count":12,"title":["Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable\u2010risk localized prostate cancer"],"prefix":"10.1002","volume":"113","author":[{"given":"William Kevin","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymen","family":"Elfiky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"San\u2010San","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Bogart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,11,6]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_5_2_2","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1679::AID-CNCR24>3.0.CO;2-Y"},{"doi-asserted-by":"publisher","key":"e_1_2_5_3_2","DOI":"10.1002\/1097-0142(19931215)72:12 <3793::AID-CNCR2820721706>3.0.CO;2-U"},{"doi-asserted-by":"publisher","key":"e_1_2_5_4_2","DOI":"10.1016\/S0022-5347(01)66888-5"},{"doi-asserted-by":"publisher","key":"e_1_2_5_5_2","DOI":"10.1016\/S0022-5347(01)62546-1"},{"doi-asserted-by":"publisher","key":"e_1_2_5_6_2","DOI":"10.1002\/1097-0142(19930901)72:5<1709::AID-CNCR2820720535>3.0.CO;2-O"},{"doi-asserted-by":"publisher","key":"e_1_2_5_7_2","DOI":"10.1016\/0360-3016(95)00123-G"},{"key":"e_1_2_5_8_2","first-page":"681","volume-title":"Genitourinary Oncology","author":"D'Amico AV","year":"2000"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0094-0143(21)00924-1","article-title":"Serum PSA after anatomic radical retropubic prostatectomy. The Johns Hopkins experience after 10 years","volume":"20","author":"Partin AW","year":"1993","journal-title":"Urol Clin North Am"},{"doi-asserted-by":"publisher","key":"e_1_2_5_10_2","DOI":"10.1016\/S0022-5347(01)67067-8"},{"doi-asserted-by":"publisher","key":"e_1_2_5_11_2","DOI":"10.1016\/S0022-5347(01)65645-3"},{"doi-asserted-by":"publisher","key":"e_1_2_5_12_2","DOI":"10.1016\/S0090-4295(99)80053-3"},{"doi-asserted-by":"publisher","key":"e_1_2_5_13_2","DOI":"10.1056\/NEJM199707313370502"},{"doi-asserted-by":"publisher","key":"e_1_2_5_14_2","DOI":"10.1200\/JCO.1997.15.3.1013"},{"doi-asserted-by":"publisher","key":"e_1_2_5_15_2","DOI":"10.1200\/JCO.2000.18.9.1936"},{"doi-asserted-by":"publisher","key":"e_1_2_5_16_2","DOI":"10.1200\/JCO.2001.19.1.44"},{"doi-asserted-by":"publisher","key":"e_1_2_5_17_2","DOI":"10.1016\/S0360-3016(02)02829-8"},{"doi-asserted-by":"publisher","key":"e_1_2_5_18_2","DOI":"10.1200\/JCO.2003.11.023"},{"doi-asserted-by":"publisher","key":"e_1_2_5_19_2","DOI":"10.1016\/j.ijrobp.2007.04.003"},{"key":"e_1_2_5_20_2","first-page":"289","article-title":"Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiotherapy","volume":"3","author":"Khil MS","year":"1997","journal-title":"Cancer J Sci Am"},{"doi-asserted-by":"publisher","key":"e_1_2_5_21_2","DOI":"10.1016\/S0360-3016(00)01375-4"},{"doi-asserted-by":"publisher","key":"e_1_2_5_22_2","DOI":"10.1016\/S0090-4295(02)02519-0"},{"doi-asserted-by":"publisher","key":"e_1_2_5_23_2","DOI":"10.1200\/JCO.2004.02.001"},{"doi-asserted-by":"publisher","key":"e_1_2_5_24_2","DOI":"10.1016\/j.ijrobp.2005.07.209"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23910","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:13:02Z","timestamp":1760296382000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23910"}},"subtitle":["Results of Cancer and Leukemia Group B 99811"],"short-title":[],"issued":{"date-parts":[[2008,11,6]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1002\/cncr.23910"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23910","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2008,11,6]]}}}